Carisma Therapeutics, Inc. (CARM)
NASDAQ: CARM · Real-Time Price · USD
0.823
-0.025 (-2.98%)
Nov 22, 2024, 4:00 PM EST - Market closed

Company Description

Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States.

The company’s ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.

It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases.

The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017.

The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Carisma Therapeutics, Inc.
Carisma Therapeutics logo
Country United States
Founded 2016
Industry Biotechnology
Sector Healthcare
Employees 107
CEO Steven Kelly

Contact Details

Address:
3675 Market Street, Suite 200
Philadelphia, Pennsylvania 19104
United States
Phone 267 491 6422
Website carismatx.com

Stock Details

Ticker Symbol CARM
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001485003
CUSIP Number 14216R101
ISIN Number US14216R1014
Employer ID 26-2025616
SIC Code 2834

Key Executives

Name Position
Steven Kelly President, Chief Executive Officer and Director
Michael Klichinsky Ph.D., Pharm.D., PharmD Co-Founder and Chief Scientific Officer
Richard S. Morris CPA Chief Financial Officer, Chief Compliance Officer, Treasurer, Prin. Financial Off. and Prin. Acc. Off.
Dr. Saar Gill M.D., Ph.D. Co-Founder and Chairman of Scientific Advisory Board
Eric H. Siegel J.D., MBA General Counsel and Corporate Secretary
Terry Shields Senior Vice President of Human Resources
Tom Wilton Chief Business Officer
Dr. Eugene P. Kennedy F.A.C.S., M.D. Chief Medical Officer
Kenneth Locke Senior Vice President of Technical Operations

Latest SEC Filings

Date Type Title
Nov 7, 2024 10-Q Quarterly Report
Nov 7, 2024 8-K Current Report
Oct 30, 2024 8-K Current Report
Oct 11, 2024 8-K Current Report
Aug 8, 2024 10-Q Quarterly Report
Aug 8, 2024 8-K Current Report
Jul 9, 2024 8-K Current Report
Jul 2, 2024 8-K Current Report
Jul 1, 2024 8-K Current Report
Jun 27, 2024 8-K Current Report